243 related articles for article (PubMed ID: 28609389)
1. Time to first occurrence of breast pain and vaginal bleeding in phase 3 trials of CE/BZA.
Pinkerton JV; Bushmakin AG; Bobula J; Lavenberg J; Komm BS; Abraham L
Menopause; 2017 Dec; 24(12):1372-1377. PubMed ID: 28609389
[TBL] [Abstract][Full Text] [Related]
2. Vaginal bleeding/spotting with conjugated estrogens/bazedoxifene, conjugated estrogens/medroxyprogesterone acetate, and placebo.
Kagan R; Abreu P; Andrews E
Postgrad Med; 2018 Nov; 130(8):687-693. PubMed ID: 30280946
[TBL] [Abstract][Full Text] [Related]
3. Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials.
Mirkin S; Pinkerton JV; Kagan R; Thompson JR; Pan K; Pickar JH; Komm BS; Archer DF
J Womens Health (Larchmt); 2016 May; 25(5):431-42. PubMed ID: 27058301
[TBL] [Abstract][Full Text] [Related]
4. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
Mirkin S; Komm BS; Pan K; Chines AA
Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989
[TBL] [Abstract][Full Text] [Related]
5. Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide.
Palacios S; Currie H; Mikkola TS; Dragon E
Maturitas; 2015 Apr; 80(4):435-40. PubMed ID: 25684082
[TBL] [Abstract][Full Text] [Related]
6. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
Parish SJ; Gillespie JA
Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials.
Pinkerton JV; Abraham L; Bushmakin AG; Cappelleri JC; Racketa J; Shi H; Chines AA; Mirkin S
J Womens Health (Larchmt); 2014 Jan; 23(1):18-28. PubMed ID: 24206058
[TBL] [Abstract][Full Text] [Related]
8. Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Vasomotor Symptoms in the Selective Estrogens, Menopause, and Response to Therapy Trials.
Archer DF; Freeman EW; Komm BS; Ryan KA; Yu CR; Mirkin S; Pinkerton JV
J Womens Health (Larchmt); 2016 Nov; 25(11):1102-1111. PubMed ID: 27676118
[TBL] [Abstract][Full Text] [Related]
9. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
Pinkerton JV; Utian WH; Constantine GD; Olivier S; Pickar JH
Menopause; 2009; 16(6):1116-24. PubMed ID: 19546826
[TBL] [Abstract][Full Text] [Related]
10. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
[TBL] [Abstract][Full Text] [Related]
11. Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables: a randomized placebo- and active-controlled trial.
Skouby SO; Pan K; Thompson JR; Komm BS; Mirkin S
Menopause; 2015 Jun; 22(6):640-9. PubMed ID: 25405570
[TBL] [Abstract][Full Text] [Related]
12. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
Pinkerton JV; Pickar JH; Racketa J; Mirkin S
Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of efficacy and safety of conjugated estrogens/bazedoxifene in a Latin American population.
Palacios S; Arias L; Lavenberg J; Pan K; Mirkin S; Komm BS
Climacteric; 2016 Jun; 19(3):261-7. PubMed ID: 26940720
[TBL] [Abstract][Full Text] [Related]
14. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
Pinkerton JV; Harvey JA; Lindsay R; Pan K; Chines AA; Mirkin S; Archer DF;
J Clin Endocrinol Metab; 2014 Feb; 99(2):E189-98. PubMed ID: 24438370
[TBL] [Abstract][Full Text] [Related]
15. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women.
Archer DF; Lewis V; Carr BR; Olivier S; Pickar JH
Fertil Steril; 2009 Sep; 92(3):1039-1044. PubMed ID: 19635614
[TBL] [Abstract][Full Text] [Related]
16. Direct and indirect effects of conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women.
Abraham L; Bushmakin AG; Dragon E; Komm BS; Pinkerton JV
Maturitas; 2016 Dec; 94():173-179. PubMed ID: 27823739
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.
Lobo RA; Pinkerton JV; Gass MLS; Dorin MH; Ronkin S; Pickar JH; Constantine G
Fertil Steril; 2009 Sep; 92(3):1025-1038. PubMed ID: 19635615
[TBL] [Abstract][Full Text] [Related]
18. Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials.
Pinkerton JV; Pickar JH; Ryan KA; Yu CR; Mirkin S; Komm BS
Menopause; 2016 Jun; 23(6):611-20. PubMed ID: 27163519
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular safety of conjugated estrogens plus bazedoxifene: meta-analysis of the SMART trials.
Komm BS; Thompson JR; Mirkin S
Climacteric; 2015; 18(4):503-11. PubMed ID: 25511453
[TBL] [Abstract][Full Text] [Related]
20. Time to transient and stable reductions in hot flush frequency in postmenopausal women using conjugated estrogens/bazedoxifene.
Pinkerton JV; Bushmakin AG; Abraham L; Komm BS; Bobula J
Menopause; 2017 Sep; 24(9):1011-1016. PubMed ID: 28463874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
